![Roberto Bellini](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: - $ in data 30/06/2026
Roberto Bellini currently works at BIOTECanada, as Vice Chairman from 2016, Klox Technologies Europe Ltd., as Director, Inhibikase Therapeutics, Inc., as Independent Director from 2025, and Bsquared Capital, Inc., as Managing Partner from 2023.
Mr. Bellini also formerly worked at BELLUS Health, Inc., as President, CEO & Head-Investor Relations from 2010 to 2012, Thallion Pharmaceuticals, Inc., as Independent Director from 2010 to 2013, CellCarta Biosciences, Inc., as Director, Picchio Pharma, Inc., as Executive Vice President, and Prognomix, Inc., as Vice President-Corporate Development.
Mr. Bellini received his undergraduate degree in 2002 from McGill University.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 26/06/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 14/02/2025 |
BIOTECanada
 BIOTECanada BiotechnologyHealth Technology Engages in research and development in biotechnology | Direttore/Membro del Consiglio | 04/05/2016 |
FB Dermatology Ltd.
 FB Dermatology Ltd. Pharmaceuticals: OtherHealth Technology Provides skin treatment services | Direttore/Membro del Consiglio | - |
| Società | Posizione | Fine |
|---|---|---|
| BELLUS HEALTH | Amministratore Delegato | 30/06/2023 |
| THALLION PHARMACEUTICALS INC. | Direttore/Membro del Consiglio | 24/04/2013 |
Picchio Pharma, Inc.
 Picchio Pharma, Inc. Pharmaceuticals: GenericHealth Technology Engages in acquiring, developing, and commercializing new therapeutic products | Corporate Officer/Principal | 01/12/2009 |
Prognomix, Inc.
 Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Develops market molecular diagnostic kits for testing of diabetes complications | Corporate Officer/Principal | - |
CellCarta Biosciences, Inc.
 CellCarta Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as specialty contract research laboratory | Direttore/Membro del Consiglio | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 9 |
|---|---|
BELLUS Health, Inc.
 BELLUS Health, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutics for the treatment of refractory chronic disease | Health Technology |
Picchio Pharma, Inc.
Picchio Pharma, Inc. Pharmaceuticals: GenericHealth Technology Engages in acquiring, developing, and commercializing new therapeutic products | Health Technology |
McGill University
 McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Thallion Pharmaceuticals, Inc.
 Thallion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops new pharmaceutical products | Health Technology |
CellCarta Biosciences, Inc.
CellCarta Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as specialty contract research laboratory | Commercial Services |
BIOTECanada
BIOTECanada BiotechnologyHealth Technology Engages in research and development in biotechnology | Health Technology |
Prognomix, Inc.
Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Develops market molecular diagnostic kits for testing of diabetes complications | Health Technology |
Inhibikase Therapeutics, Inc.
 Inhibikase Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes small-molecule kinase inhibitor therapeutics for neurological diseases | Health Technology |
FB Dermatology Ltd.
FB Dermatology Ltd. Pharmaceuticals: OtherHealth Technology Provides skin treatment services | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
